Klacid 50 mg/ ml Norge - norsk - Statens legemiddelverk

klacid 50 mg/ ml

mylan healthcare norge as - klaritromycin - granulat til mikstur, suspensjon - 50 mg/ ml

Simvastatin Hexal 80 mg Norge - norsk - Statens legemiddelverk

simvastatin hexal 80 mg

hexal a/s - simvastatin - tablett, filmdrasjert - 80 mg

Topiramat Bluefish 200 mg Norge - norsk - Statens legemiddelverk

topiramat bluefish 200 mg

bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 200 mg

Topiramat Bluefish 25 mg Norge - norsk - Statens legemiddelverk

topiramat bluefish 25 mg

bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 25 mg

Topiramat Bluefish 50 mg Norge - norsk - Statens legemiddelverk

topiramat bluefish 50 mg

bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 50 mg

Topiramat Bluefish 100 mg Norge - norsk - Statens legemiddelverk

topiramat bluefish 100 mg

bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 100 mg

Zolpidem Aurobindo 10 mg Norge - norsk - Statens legemiddelverk

zolpidem aurobindo 10 mg

aurobindo pharma (malta) limited - zolpidemtartrat - tablett, filmdrasjert - 10 mg

Zolpidem Aurobindo 5 mg Norge - norsk - Statens legemiddelverk

zolpidem aurobindo 5 mg

aurobindo pharma (malta) limited - zolpidemtartrat - tablett, filmdrasjert - 5 mg

Daurismo Den europeiske union - norsk - EMA (European Medicines Agency)

daurismo

pfizer europe ma eeig - glasdegib maleate - leukemi, myeloid, akutt - antineoplastiske midler - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Enhertu Den europeiske union - norsk - EMA (European Medicines Agency)

enhertu

daiichi sankyo europe gmbh - trastuzumab deruxtecan - bryst neoplasms - antineoplastiske midler - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.